Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children1510.24287/1726-1708-2017-16-4-98-106СтатьиOsteopenia and osteoporosis after allogeneic hematopoietic stem cell transplantation, features of bone mineral turnover pathology in childrenОстеопения и остеопороз после аллогенной трансплантации гемопоэтических стволовых клеток, особенности нарушений костного минерального обмена у детейhttps://orcid.org/0000-0002-0566-053XSkvortsovaY. V.СкворцоваЮ.В.
Russian Federation

MD, hematologist of HSCT Department #2

Russia 117997, Moscow, Samory Mashela st., 1+7 (915) 069-3743

yuscvo@mail.ruBalashovD. N.БалашовД.Н.
Russian Federation
https://orcid.org/0000-0002-0016-6698MaschanA. A.МасчанА.А.
Russian Federation
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, ImmunologyФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России091120171649810609082018Copyright ©; 2017, «D. Rogachev NMRCPHOI»Copyright ©; 2017, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2017«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/15

Among the numerous late effects of allogeneic hematopoietic stem cell transplantation (HSCT) the bone turnover pathology remains one of the frequent. Osteopenia and osteoporosis are multifactorial, progressive and long-term disturbances. They can lead to bone fractures and disability and significantly reduce the quality of life. In-time diagnostic of osteopenia and osteoporosis, appropriate and individualized therapeutic approach allow to improve the prognosis of patients. This article describes pathogenesis, diagnostic and recent treatment options of bone mineral pathology after allogeneic HSCT. Pecularities of these complications in children population are reviewed separately.

Среди множества отдаленных эффектов аллогенной трансплантации гемопоэтических стволовых клеток (алло-ТГСК) нередкой проблемой является патология костного минерального обмена. Остеопения и остеопороз - многофакторные, прогрессирующие и длительные нарушения, которые приводят к переломам костей и инвалидизации, существенно снижают качество жизни пациентов. Своевременная диагностика остеопении и остеопороза, правильный и индивидуализированный подход к терапии позволяют улучшить прогноз заболевания. В статье описаны патогенез, диагностика и современные подходы к лечению патологии костного обмена после алло-ТГСК. Отдельно освещены особенности данных нарушений в детской популяции.

allogeneic hematopoietic stem cell transplantationlate effectsosteopeniaosteoporosisаллогенная трансплантация гемопоэтических стволовых клетокпоздние осложненияостеопенияостеопорозHautmann A.H., Elad S., Lawitschka A., et al. Metabolic bone diseases in patients after allogeneic hematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. Transpl Int 2011 Sep; 24 (9): 867-79.Tauchmanovà L., Colao A., Lombardi G., et al. Bone loss and its management in long-term survivors from allogeneic stem cell transplantation. J Clin Endocrinol Metab 2007 Dec; 92 (12): 4536-45.Abou-Mourad Y.R., Lau B.C., Barnett M.J., et al. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplant 2010 Feb; 45 (2): 295-302.Yao S., McCarthy P.L., Dunford L.M., et al. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. Bone Marrow Transplant 2008 Feb; 41 (4): 393-8.Yao S., McCarthy P.L., Dunford L.M., et al. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. Bone Marrow Transplant 2008 Feb; 41 (4): 393-8.Petropoulou A.D., Porcher R., Herr A.L., et al. Prospective assessment of bone turnover and clinical bone diseases after allogeneic hematopoietic stem-cell transplantation. Transplantation 2010 Jun 15; 89 (11): 1354-61.Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993; 94: 646.McClune B.L., Polgreen L.E., Burmeister L.A., et al. Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients. Bone Marrow Transplant 2011 Jan; 46 (1): 1-9.Baim S., Leonard M.B., Bianchi M.L., et al. Official Positions of the Inter- national Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densi-tom 2008 Jan-Mar; 11 (1): 6-21.Gordon C.M., Bachrach L.K., Carpenter T.O., et al. Dual energy X-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD Pediatric Official Positions. J Clin Densitom 2008 Jan-Mar; 11 (1): 43-58.Majhail N.S., Rizzo J.D., Lee S.J., et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Rev Bras Hematol Hemoter 2012; 34 (2): 109-33.Weilbaecher K.N. Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000; 6 (2A): 165-74.Hamdy N.A. Targeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosis. Curr Opin Investig Drugs 2007 Apr; 8 (4): 299-303.Petryk A., Bergemann T.L., Polga K.M., et al. Prospective study of changes in bone mineral density and turnover in children after hematopoietic cell transplantation. J Clin Endocrinol Metab 2006 Mar; 91 (3): 899-905.Schulte C., Beelen D.W., Schaefer U.W., Mann K. Bone loss in long-term survivors after transplantation of hematopoietic stem cells: a prospective study. Osteoporos Int 2000; 11 (4): 344-53.Schimmer A.D., Minden M.D., Keating A. Osteoporosis after blood and marrow transplantation: clinical aspects. Biol Blood Marrow Transplant 2000; 6 (2A): 175-81.Savani B.N., Donohue T., Kozanas E., et al. Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007 May; 13 (5): 517-20.Lee W.Y., Baek K.H., Rhee E.J., et al. Impact of circulating bone-resorbing cytokines on the subsequent bone loss following bone marrow transplantation. Bone Marrow Transplant 2004 Jul; 34 (1): 89-94.Baek K.H., Oh K.W., Lee W.Y., et al. Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism. Bone 2006 Dec; 39 (6): 1352-60.Buchs N., Helg C., Collao C., et al. Allogeneic bone marrow transplantation is associated with a preferential femoral neck bone loss. Osteoporos Int 2001; 12 (10): 880-6.De Vries F., Bracke M., Leufkens H.G., et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 2007 Jan; 56 (1): 208-14.Kanis J.A., Burlet N., Cooper C., et al. European guidelines for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008 Apr; 19 (4): 399-428. PMID: 18266020.Carpenter P.A., Kitko C.L., Elad S., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2015 Jul; 21 (7): 1167-87.van Staa T.P., Leufkens H.G., Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002 Oct; 13 (10): 777-87.Rizzo J.D., Wingard J.R., Tichelli A., Lee S.J., Van Lint M.T., Burns L.J., et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2006 Feb; 12 (2): 138-51.Hausmann A., Hill W., Stemmler H.J., et al. Chemother Res Pract. 2012; 2012: 858590. Epub 2012 Apr 10. PMID: 22550587.Drake M.T., Clarke B.L., Khosla S. Bisphosphonates: Mechanism of Action and Role in Clinical Practice. Mayo Clin